A phase II trial of erlotinib monotherapy for pretreated elderly patients with advanced EGFR wild-type non-small cell lung cancer.
about
Erlotinib as second- or third-line treatment in elderly patients with advanced non-small cell lung cancer: Keio Lung Oncology Group Study 001 (KLOG001)A randomized phase II trial of erlotinib vs. S-1 as a third- or fourth-line therapy for patients with wild-type EGFR non-small cell lung cancer (HOT1002).
P2860
A phase II trial of erlotinib monotherapy for pretreated elderly patients with advanced EGFR wild-type non-small cell lung cancer.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
A phase II trial of erlotinib ...... pe non-small cell lung cancer.
@ast
A phase II trial of erlotinib ...... pe non-small cell lung cancer.
@en
type
label
A phase II trial of erlotinib ...... pe non-small cell lung cancer.
@ast
A phase II trial of erlotinib ...... pe non-small cell lung cancer.
@en
prefLabel
A phase II trial of erlotinib ...... pe non-small cell lung cancer.
@ast
A phase II trial of erlotinib ...... pe non-small cell lung cancer.
@en
P2093
P2860
P1433
P1476
A phase II trial of erlotinib ...... pe non-small cell lung cancer.
@en
P2093
Akio Oishi
Hiroshi Yokouchi
Hiroyuki Minemura
Keisuke Azuma
Ken-ichiro Hirai
Kengo Oshima
Kenya Kanazawa
Mitsuru Munakata
Satoko Sekine
Taeko Ishii
P2860
P2888
P356
10.1186/S13104-015-1214-9
P577
2015-06-05T00:00:00Z
P5875
P6179
1048884564